Pharmaceutical

How can Glycyl-L-histidyl-L-lysine supply quality be tested? Glycyl-L-histidyl-L-lysine Discover how to audit and secure a compliant Glycyl-L-histidyl-L-lysine (GHK, CAS 49557-75-7) supply chain. Learn supplier reliability metrics, certification checks, logistics risks, and GMP-grade sourcing strategies for 2026.
What purity matters for Glycyl-L-histidyl-L-lysine supply? Glycyl-L-histidyl-L-lysine Explore pharmaceutical-grade GHK (CAS 49557-75-7) purity benchmarks, impurity profiling, analytical testing (HPLC, MS, ICP), and injection-grade safety standards for clinical applications and peptide manufacturing compliance.
Global Biopharma Layoffs May 2026 Layoffs Layoff Passage Bio Reckitt Benckiser Takeda Novartis Biopharma layoffs in 2026 continue to reshape the industry as companies including Takeda, Novartis, Replimune, Passage Bio and Autolus Therapeutics cut jobs, restructure operations and reduce costs amid pipeline setbacks, strategic reorganizations and market pressures.
Global Biopharma Layoffs April 2026 Layoffs Layoff Novo Nordisk BioNTech Global Biopharma companies including Novo Nordisk, IO Biotech, and BioNTech announce workforce reductions in April 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs March 2026 Layoffs Layoff Merck Vertex Alltrna Bayer Takeda Novartis Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Johnson & Johnson Full Year 2025 Financial Report Johnson & Johnson Financial statements Johnson & Johnson posts steady 2025 growth with $94.2B revenue, driven by pharmaceuticals ($60.4B) and medical technology. Strong innovation and global performance set a positive outlook for 2026.
AstraZeneca Full Year 2025 Financial Report AstraZeneca Financial statements AstraZeneca reports 2025 revenue of $58.7B, led by strong oncology growth, a record China performance, and a catalyst-rich pipeline driving momentum into 2026 and beyond.
BMS Full Year 2025 Financial Report BMS Financial statements Bristol Myers Squibb reports 2025 results with stable revenue, a sharp rebound in profitability, strong growth from new products, and resilient Eliquis sales reaching $14.4 billion despite patent pressures.
AbbVie Full Year 2025 Financial Report AbbVie Financial statements AbbVie reports strong 2025 results: revenue rises 9% to $61.2B, driven by Skyrizi and Rinvoq. Profits grow, international markets expand, and innovation sets stage for 2026.
GSK Full Year 2025 Financial Report GSK Financial statements GSK reported £32.7B revenue in 2025, up 4% YoY, driven by specialty medicines and vaccines. Core profit rose 7%, with strong R&D pipeline and steady global growth supporting 2026 outlook.

< Pre 1...35 36 373839 40 41...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles